Analgesic efficacy and safety of percutaneous thermal ablation plus cementoplasty for painful bone metastases : a systematic review and meta-analysis
© 2024. The Author(s) under exclusive licence to Japan Society of Clinical Oncology..
PURPOSE: To conduct a systematic review and meta-analysis of publications to evaluate the analgesic efficacy and safety of percutaneous thermal ablation (PTA) plus percutaneous cementoplasty (PCP) (PTA + PCP) for painful bone metastases.
METHODS: We searched PubMed, Cochrane Library and Embase for articles published up to October 2022. Outcomes were a 10-point pain scale, morphine equivalents daily dose (MEDD) and complications. A subgroup confined to spinal bone metastases was analyzed.
RESULTS: Twenty-one articles were selected for the analysis. The 21 selected articles involved a total of 661 cases. The pooled pain scales at pre-PTA + PCP, 1 day, 1 week and 1-, 3-, and 6 months post-PTA + PCP were 7.60 (95% confidence interval [CI], 7.26-7.95, I2 = 89%), 3.30 (95% CI, 2.25-4.82, I2 = 98%), 2.58 (95% CI, 1.99-3.35, I2 = 94%), 2.02 (95% CI, 1.50-2.71, I2 = 93%), 1.78 (95% CI, 1.26-2.53, I2 = 95%), and 1.62 (95% CI, 1.14-2.31, I2 = 88%), and in the subgroup, 7.97 (95% CI, 7.45-8.52, I2 = 86%), 3.01 (95% CI, 1.43-6.33, I2 = 98%), 2.95 (95% CI, 1.93-4.51, I2 = 95%), 2.34 (95% CI, 1.82-3.01, I2 = 68%), 2.18 (95% CI, 1.57-3.03, I2 = 78%), and 2.01 (95% CI, 1.16-3.48, I2 = 86%). Mean MEDD decreased up to 3 months post-PTA + PCP in 4 articles. The overall pooled major complication rate was 4% (95% CI, 2-6%, I2 = 2%).
CONCLUSIONS: The updated systematic review and meta-analysis indicates that PTA + PCP for painful bone metastases is safe, and can lead to rapid and sustained pain reduction.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
International journal of clinical oncology - 29(2024), 4 vom: 31. März, Seite 372-385 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Matsumoto, Tomohiro [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Ablation techniques |
|---|
| Anmerkungen: |
Date Completed 26.03.2024 Date Revised 26.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10147-023-02458-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367083035 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367083035 | ||
| 003 | DE-627 | ||
| 005 | 20240326235234.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10147-023-02458-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1348.xml |
| 035 | |a (DE-627)NLM367083035 | ||
| 035 | |a (NLM)38217754 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Matsumoto, Tomohiro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Analgesic efficacy and safety of percutaneous thermal ablation plus cementoplasty for painful bone metastases |b a systematic review and meta-analysis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.03.2024 | ||
| 500 | |a Date Revised 26.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s) under exclusive licence to Japan Society of Clinical Oncology. | ||
| 520 | |a PURPOSE: To conduct a systematic review and meta-analysis of publications to evaluate the analgesic efficacy and safety of percutaneous thermal ablation (PTA) plus percutaneous cementoplasty (PCP) (PTA + PCP) for painful bone metastases | ||
| 520 | |a METHODS: We searched PubMed, Cochrane Library and Embase for articles published up to October 2022. Outcomes were a 10-point pain scale, morphine equivalents daily dose (MEDD) and complications. A subgroup confined to spinal bone metastases was analyzed | ||
| 520 | |a RESULTS: Twenty-one articles were selected for the analysis. The 21 selected articles involved a total of 661 cases. The pooled pain scales at pre-PTA + PCP, 1 day, 1 week and 1-, 3-, and 6 months post-PTA + PCP were 7.60 (95% confidence interval [CI], 7.26-7.95, I2 = 89%), 3.30 (95% CI, 2.25-4.82, I2 = 98%), 2.58 (95% CI, 1.99-3.35, I2 = 94%), 2.02 (95% CI, 1.50-2.71, I2 = 93%), 1.78 (95% CI, 1.26-2.53, I2 = 95%), and 1.62 (95% CI, 1.14-2.31, I2 = 88%), and in the subgroup, 7.97 (95% CI, 7.45-8.52, I2 = 86%), 3.01 (95% CI, 1.43-6.33, I2 = 98%), 2.95 (95% CI, 1.93-4.51, I2 = 95%), 2.34 (95% CI, 1.82-3.01, I2 = 68%), 2.18 (95% CI, 1.57-3.03, I2 = 78%), and 2.01 (95% CI, 1.16-3.48, I2 = 86%). Mean MEDD decreased up to 3 months post-PTA + PCP in 4 articles. The overall pooled major complication rate was 4% (95% CI, 2-6%, I2 = 2%) | ||
| 520 | |a CONCLUSIONS: The updated systematic review and meta-analysis indicates that PTA + PCP for painful bone metastases is safe, and can lead to rapid and sustained pain reduction | ||
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Ablation techniques | |
| 650 | 4 | |a Bone neoplasms | |
| 650 | 4 | |a Cancer pain | |
| 650 | 4 | |a Interventional radiology | |
| 650 | 4 | |a Pain management | |
| 650 | 7 | |a Analgesics |2 NLM | |
| 700 | 1 | |a Yoshimatsu, Rika |e verfasserin |4 aut | |
| 700 | 1 | |a Osaki, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Shibata, Junki |e verfasserin |4 aut | |
| 700 | 1 | |a Maeda, Hitomi |e verfasserin |4 aut | |
| 700 | 1 | |a Miyatake, Kana |e verfasserin |4 aut | |
| 700 | 1 | |a Noda, Yoshinori |e verfasserin |4 aut | |
| 700 | 1 | |a Yamanishi, Tomoaki |e verfasserin |4 aut | |
| 700 | 1 | |a Yamagami, Takuji |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of clinical oncology |d 1997 |g 29(2024), 4 vom: 31. März, Seite 372-385 |w (DE-627)NLM095566163 |x 1437-7772 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2024 |g number:4 |g day:31 |g month:03 |g pages:372-385 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10147-023-02458-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2024 |e 4 |b 31 |c 03 |h 372-385 | ||